Pfizer Inc.
(FILES)This January 11, 2011 file photo shows a screen image of the Google logo in Washington,DC. Google May 22, 2012 finalized its $12.5 billion deal for Motorola Mobility, a key manufacturer of smartphones and other devices which puts the Internet giant in head-to-head competition with Apple. "The acquisition will enable Google to supercharge the Android ecosystem and will enhance competition in mobile computing," the California-based Internet giant said in a statement. AFP PHOTO/KAREN BLEIER/FILESKAREN BLEIER/AFP/GettyImages
Connections
Quotes
The study of Lyrica for this condition is an example of Pfizer's dedication to better understanding neuropathic pain and to providing data and developing treatments to address areas of patient need.
That snare had a breaking strength of two tons. The dart was full of something called Telazol, brought you to by Pfizer, the same people who make Zoloft and Viagra
The story here is that Pfizer is dealing with its Lipitor patent loss surprisingly well ... When you lose the biggest medicine in the world and your earnings per share only fall 3 percent, that's a lot better than people expected a few years ago. Pfizer is mitigating the patent loss by cutting costs and bringing in good new drugs.More quotes »
Newsday's coverage
-
Nestle to buy Pfizer's infant-nutrition business
offer beat a rival joint bid by Groupe Danone and Mead Johnson Nutrition Co. for the infant-nutrition business, which Pfizer had put up for sale last July along with a separate animal-health business unit.Pfizer, the world's largest drug maker, has been shedding Read more »
-
Summary Box: Pfizer triples pay for new CEO Read
BUMP: Pfizer CEO Ian Read saw compensation nearly triple to $18 million in 2011, his first full year heading the drugmaker. That includes $1.7 million in salary and stock and option awards of $12.5 million.SOME PROGRESS: Read has cut costs, restructured Pfizer's Read more »
-
Pfizer CEO's pay triples to $18M in first year
in history with peak sales of nearly $13 billion -- now down sharply since Lipitor got U.S. generic competition on Nov. 30.Pfizer, which had total sales of $67.4 billion last year, has managed to retain significantly more U.S. Lipitor revenue than would normally Read more »
-
Merck: FDA won't OK its combo cholesterol drug now
can approve the medicine.The Merck experimental drug combines the company's cholesterol drug Zetia with a generic version of rival Pfizer Inc. 's Lipitor , which had been the top-selling drug of all time.Merck says company officials will talk with the FDA Read more »
-
Pfizer, Bristol: FDA ruling on Eliquis postponed
other two are already approved in the U.S. All three could become blockbusters, bringing their makers much-needed new revenue.Pfizer and Bristol-Myers said in a statement that they will continue to work closely with the FDA on the review."At this stage there Read more »
Around the web
-
Merck CEO puts himself in diversification-is-good camp
Pfizer's slimming down by hiving off pieces of the company. Abbott Laboratories is preparing to spin off its pharma business completely. But Merck ($MRK) CEO Ken Frazier is having none of that. "My philosophy is fix what is broke, don't do the fad of the 12:08 PM from FiercePharma Read more »
-
Merck & Co., Inc.'s Says He Won't Follow Pfizer Inc., Abbott Laboratories in Splitting Company
& Co. (MRK) Chief Executive Officer Ken Frazier said he doesn’t plan on breaking up the company by splitting off businesses the way Pfizer Inc. (PFE) and Abbott Laboratories are doing. “My philosophy is fix what is broke, don’t do the fad of the day,” Frazier 11:02 AM from Biospace Read more »
-
CHMP in Favor of Pfizer's Axitinib - Analyst Blog
(PFE - Analyst Report) recently announced that its renal cell cancer candidate, axitinib, received a positive opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA). Pfizer is seeking EU approval for the use of 9:57 AM from Zacks Investment Research Read more »
-
Published Review of Individual Smoking Cessation Treatments Fails to Mention Electronic Cigarettes; Another Example of the Results of Financial Conflict of Interest?
and the UKCTCS received payment from Pfizer, McNeil and Xenova (now Celtic) for consultancy, and that PA received payment from Pfizer for talks and educational presentations." So at least part of the funding received was related to consultation on the drug 5/30/12 from The Rest of the Story Read more »
-
Why Big Pharma Stocks Have Been Performing Poorly And Why AstraZeneca Is A Buy
One can see that only the Swiss Novartis had kept pace with the S&P for the period, AstraZeneca returned -5% in ten years and Pfizer plunged to -35% of its 2002 value. In this chart, dividends, which are substantial for these companies, cannot be seen so the 6:55 AM from Seeking Alpha Read more »
